Serum HER2 levels are increased in patients with chronic heart failure

[1]  Greg Yothers,et al.  Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Rohrbach,et al.  Neuregulin receptors erbB2 and erbB4 in failing human myocardium , 2005, Basic Research in Cardiology.

[3]  E. D. de Vries,et al.  The dilemma of the strive for apoptosis in oncology: mind the heart. , 2005, Critical reviews in oncology/hematology.

[4]  R. Hajjar,et al.  Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[5]  J. Bart,et al.  Preclinical characterisation of 111In‐DTPA‐trastuzumab , 2004, British journal of pharmacology.

[6]  D. J. Veldhuisen,et al.  Biodistribution and pharmacokinetics of radiolabeled trastuzumab in HER2-positive metastatic breast cancer , 2004 .

[7]  W. Wilczak,et al.  Prognostic and Predictive Impact of the HER-2/neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer , 2004, Breast Cancer Research and Treatment.

[8]  W. Lichtenegger,et al.  Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™) , 2003, Breast Cancer Research and Treatment.

[9]  Douglas L Mann,et al.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.

[10]  O. Frazier,et al.  Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  Carmen Birchmeier,et al.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Nieminen,et al.  Soluble tumor necrosis factor receptor levels identify a subgroup of heart failure patients with increased cardiomyocyte apoptosis. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[13]  Susumu Minamisawa,et al.  ErbB2 is essential in the prevention of dilated cardiomyopathy , 2002, Nature Medicine.

[14]  B. Wörmann,et al.  Trastuzumab and breast cancer. , 2001, The New England journal of medicine.

[15]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[16]  K. Chien,et al.  Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. , 2000, Seminars in oncology.

[17]  R. D. de Boer,et al.  Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure. , 2000, Journal of cardiac failure.

[18]  B. Lloveras,et al.  Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  B. Lloveras,et al.  Circulating HER 2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer 1 , 2000 .

[20]  D. Sawyer,et al.  NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70S6K, and MEK-MAPK-RSK. , 1999, American journal of physiology. Heart and circulatory physiology.

[21]  B. Lorell,et al.  Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. , 1999, Circulation.

[22]  D. Opel,et al.  Neuregulins Promote Survival and Growth of Cardiac Myocytes , 1998, The Journal of Biological Chemistry.

[23]  R. Virmani,et al.  Apoptosis in myocytes in end-stage heart failure. , 1996, The New England journal of medicine.

[24]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[25]  D. Mann,et al.  Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. , 1996, Circulation.

[26]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[27]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[28]  P. Singal,et al.  Subcellular effects of adriamycin in the heart: a concise review. , 1987, Journal of molecular and cellular cardiology.

[29]  B. Gandevia,et al.  DECLARATION OF HELSINKI , 1964, Definitions.

[30]  Rickham Pp.  Human Experimentation: Code of Ethics of the World Medical Association (Declaration of Helsinki). , 1964, Canadian Medical Association journal.

[31]  P. P. Rickham.  HUMAN EXPERIMENTATION. CODE OF ETHICS OF THE WORLD MEDICAL ASSOCIATION. DECLARATION OF HELSINKI. , 1964, British medical journal.